Respiratory syncytial virus vaccination and immunoprophylaxis: realising the potential for protection of young children

The Lancet, Год журнала: 2024, Номер 404(10458), С. 1157 - 1170

Опубликована: Сен. 1, 2024

Язык: Английский

---

Respiratory Syncytial Virus Vaccination in Pregnancy

Obstetrics and Gynecology, Год журнала: 2025, Номер 145(2), С. 144 - 146

Опубликована: Янв. 2, 2025

Caitlin Dugdale and Andrea Ciaranello are from the Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts; [email protected] protected]. Emily Santos is Brown University, Providence, Rhode Island; Financial Disclosure The authors did not report any potential conflicts interest.

Язык: Английский

---

Safety and Efficacy of Vaccines During Pregnancy: A Systematic Review

Cureus, Год журнала: 2025, Номер unknown

Опубликована: Янв. 9, 2025

Maternal immunization is a safe and effective strategy for protecting mothers infants from vaccine-preventable diseases. This systematic review evaluated the safety efficacy of various vaccines administered during pregnancy, focusing on maternal infant outcomes. A comprehensive literature search was conducted in PubMed, Scopus, Web Science to identify relevant studies. The used terms combinations such as ("maternal vaccination" OR "vaccination pregnancy") AND ("safety" "efficacy" "immunogenicity") ("influenza" "DTaP" "respiratory syncytial virus" "group B streptococcus" "COVID-19"). Boolean operators "AND" "OR" enhanced precision filtered limited results studies published 2018 2024. Eight were included after applying inclusion exclusion criteria. Influenza, diphtheria-tetanus-pertussis, respiratory virus, group streptococcus, COVID-19 are when pregnancy. These elicit robust immune responses pregnant women, with efficient transplacental antibody transfer providing passive immunity newborns. Adverse effects mostly mild moderate similar those observed nonpregnant individuals. No significant increase adverse pregnancy or neonatal outcomes associated vaccination. Most randomized controlled trials (had low risk bias, thus supporting reliability findings. However, vaccine hesitancy remains challenge, highlighting need transparent communication between healthcare providers women. Future research should focus long-term health outcomes, safety, immunogenicity diverse populations, strategies optimize timing enhance persistence. supports implementation routine vaccination programs emphasizes importance addressing knowledge gaps ensuring equitable access

Язык: Английский

---

Updated Joint Position Statement on Vaccines From the Society for Birth Defects Research and Prevention and the Organization of Teratology Information Specialists

Birth Defects Research, Год журнала: 2025, Номер 117(1)

Опубликована: Янв. 1, 2025

Язык: Английский

---

Respiratory Syncytial Virus Vaccination Is Associated With Increased Odds of Preterm Birth

Acta Paediatrica, Год журнала: 2025, Номер unknown

Опубликована: Янв. 20, 2025

ABSTRACT Aim To analyse whether respiratory syncytial virus (RSV) vaccination during pregnancy increases the odds of preterm birth. Methods A rapid review and meta‐analysis was performed. The main outcome risk (gestational week less than 37) fixed‐effects model used to pooled ratios (OR) with 95% confidence intervals (CI). Evidence certainty assessed according GRADE. Results We included six randomised controlled trials 17 656 births two observational studies 3446 births. for birth were increased in (OR 1.17, CI 1.02–1.34). No evidence a difference seen 0.93, 0.69–1.25). Combined, these showed 1.13, 1.00–1.27). rated be moderate. When restricted market‐approved vaccine, seemed RCTs 1.21, 0.98–1.49). Conclusion Based on available evidence, RSV seems associated needs continuous population‐level safety data monitoring perinatal outcomes early phases vaccine rollouts detect possible signals further confirm magnitude effect

Язык: Английский

---

Maternal Immunization and the Implementation Gap—Strengthening Respiratory Syncytial Virus Infrastructure and Preparing for the Future

JAMA Network Open, Год журнала: 2025, Номер 8(2), С. e2460743 - e2460743

Опубликована: Фев. 19, 2025

Christine A. Blauvelt, MD; Molly Zeme, BA; Aishwarya Natarajan, BSc; Adrienne Epstein, MSc, PhD; Michelle E. Roh, MPH, Amayrani Morales, Nadia Bourdoud, MPH; Valerie J. Flaherman, MD, Mary K. Prahl, Stephanie L. Gaw, PhD

Язык: Английский

---

Maternal RSVpreF and Infant Nirsevimab Immunizations Uptake During Respiratory Syncytial Virus Season

JAMA Network Open, Год журнала: 2025, Номер 8(2), С. e2460729 - e2460729

Опубликована: Фев. 19, 2025

This cohort study evaluates the use rate of respiratory syncytial virus (RSV) vaccines to prevent RSV-related lower tract disease among infants.

Язык: Английский

---

Respiratory Syncytial Virus Vaccine and Nirsevimab Uptake Among Pregnant People and Their Neonates

JAMA Network Open, Год журнала: 2025, Номер 8(2), С. e2460735 - e2460735

Опубликована: Фев. 19, 2025

Importance Two interventions to prevent severe respiratory syncytial virus (RSV) in infants were approved 2023—a bivalent prenatal RSV prefusion F protein–based (RSVpreF) vaccine and an infant monoclonal antibody (nirsevimab). Understanding their uptake clinical outcomes is essential for public health planning. Objective To describe of the RSVpreF nirsevimab. Design, Setting, Participants This retrospective cohort study was conducted at a single academic center among 647 pregnant individuals eligible vaccination (32-36 weeks’ gestation between October 15, 2023, January 31, 2024) nirsevimab (no >14 days before delivery). Exposure Pregnancy or birth during 2023-2024 season. Main Outcomes Measures administration prior hospital discharge infants. Results Of (mean [SD] age, 34.6 [6.2] years; 355 nulliparous [54.9%]; 558 privately insured [86.2%]), 414 (64.0%) received vaccine. Factors associated with higher included older birthing parent age (adjusted odds ratio [AOR], 1.09; 95% CI, 1.05-1.12), nulliparity (AOR, 1.84; 1.31-2.60), private insurance 2.19; 1.27-3.80), non-Hispanic ethnicity 2.36; CI 1.57-3.55; reference: Hispanic), receipt any COVID-19 7.12; 3.91-13.70), formula booster 5.62; 3.80-8.48), influenza 8.14; 5.38-12.50), tetanus-diphtheria-pertussis 6.86; 3.79-13.10). lower non-English language preference 0.24; 0.10-0.52), Black race 0.30; 0.16-0.57; Asian), other unknown 0.48; 0.30-0.76), multiple 0.27; 0.07-0.88). Nirsevimab administered 183 261 (70.1%) discharge. Among those who did not receive standard vaccines, 40.4% neonates (19 47) nirsevimab; declined hepatitis B vaccination, 34.0% (17 50) Respiratory coverage exceeded 80% all months period except first month which available. Preterm delivery occurred 35 RSVpreF-vaccinated (8.5%) 43 233 unvaccinated (18.5%). In nested case-control analysis preterm as outcome, there no significant association 1.03; 0.55-1.93). Conclusions Relevance this study, high. high even routine vaccines. There birth. suggests that prevention strategy both had reassuring perinatal outcomes.

Язык: Английский

---

Vaccines in Pregnancy: An Update on Recommendations From CDC's Advisory Committee on Immunization Practices

Birth Defects Research, Год журнала: 2025, Номер 117(2)

Опубликована: Фев. 1, 2025

Vaccinations in pregnancy are an essential part of prenatal care and play a critical role protecting both pregnant persons their infants from certain infectious diseases. In the United States, recommendations for vaccines made through comprehensive review currently available scientific literature, including clinical trials post-marketing surveillance data, by Advisory Committee on Immunization Practices (ACIP). The ACIP is advisory committee to US Centers Disease Control Prevention (CDC), comprised medical public health experts who develop evidence-based guidelines vaccinations, persons. has several work groups that evidence ongoing basis, full-committee meetings held at least three times year. As more data regarding safety efficacy become available, these continue evolve. To recommendations, carefully considers risks exposure agents against potential vaccination. We here current vaccinations use Recommendations divided into four categories: recommended during pregnancy, under circumstances, not or contraindicated without specific recommendations. ensure optimal healthcare providers need be familiar with

Язык: Английский

---

Respiratory syncytial virus vaccination: likely and less likely outcomes

Current Opinion in Pediatrics, Год журнала: 2025, Номер unknown

Опубликована: Март 19, 2025

Purpose of review Respiratory syncytial virus (RSV) remains a leading cause lower respiratory tract infections in infants, older adults, and high-risk populations. The recent approval new RSV vaccines monoclonal antibodies marks turning point prevention. This explores these advancements, their immediate potential long-term effects, the remaining challenges. Recent findings Several novel prevention strategies have been approved, including maternal RSVPreF vaccines, infant-targeted like Nirsevimab, for adults. These interventions significantly reduce RSV-related hospitalizations, ICU admissions, mortality, particularly groups. Early evidence also suggests benefits reducing wheezing during infancy; however, impacts on asthma development remain uncertain. Challenges such as vaccine hesitancy limited access low-resource settings pressing issues that require sustained focus. Summary are expected to alter clinical management public health by severe disease burden transmission. Further research is needed evaluate implications pediatric obstructive sleep apnea. Addressing disparities acceptance will be critical maximizing global impact.

Язык: Английский

---